Not only the global market, but also a global platform - new trends in foreign investment in China

In a medical device company's factory in Tianjin Port Free Trade Zone, technicians in clean clothes are assembling a fully automatic coagulation analyzer in front of the workstation. Parts from Europe and China are finally assembled here, tested, and sent to hospitals and laboratories around the world.

This is the first and only medical device production base of French medical device company Stago in markets outside of Europe. It took more than 20 years for this French enterprise to achieve a leap from a trader in China to a local manufacturer and then to a local innovator.

Our localization is moving from production to research and development. We are no longer just shipping products to China or moving production lines to China, but also landing our innovative research and development capabilities in China. "In the view of Sun Xiangchao, the Supply Chain and Production Director of Stago China, this greatly shortens the" reflex arc "between the" brain "of the French headquarters and the" hands "of Tianjin, China.

From "production in China" to "research and development in China" and then to "co creation with China", China is not only a "world market", but also a "world platform" that drives global innovation.

The latest data released by the Chinese Ministry of Commerce shows that nearly 4000 foreign-funded enterprises increased their investment in China in the first five months of this year. In the first half of the year, the import and export scale of foreign-funded enterprises achieved double-digit growth.

In June of this year, Danish pharmaceutical giant Novo Nordisk's global president and CEO, Dumack, announced an additional investment of 200 million yuan in its strategic production base in Tianjin during a visit to China with a global executive team to enhance the assembly and production capacity of injection pens.

Du Maike stated that China is becoming an important source of innovative drugs and is highly optimistic about the vitality and efficiency of China's pharmaceutical innovation ecosystem. The outline of China's 15th Five Year Plan emphasizes the need to accelerate the construction of a healthy China and regards biomedicine as a strategic emerging industry.

No one can ignore China and the innovation happening here, "he said." We need to bring the good experience accumulated by Novo Nordisk in developing innovative drugs in China to other markets and integrate it into the group's global strategy

China leads industrial innovation with technological innovation, and more and more multinational enterprises are placing their research and development and high-end manufacturing processes in China, enhancing global competitiveness. In the first half of the year, the import and export of bonded research and development by Chinese foreign-funded enterprises increased by 15%, accounting for nearly 80% of China's bonded research and development import and export.

At the end of last year, GE Healthcare announced that its innovation center for magnetic resonance imaging in the Eastern Hemisphere, located in Tianjin, was officially put into operation. This innovation center is the only system level magnetic resonance research and development base for GE Healthcare outside of the United States, focusing on core components such as magnets, gradients, coils, and cutting-edge AI technology research and development.

Kelly Lundy, President and CEO of GE Healthcare's Global Magnetic Resonance Business, said, "In this innovation center, not only is there an engineering team developing new technologies, processes, and clinical innovation solutions, but also locally manufactured innovative hardware equipment as support. Therefore, we can accelerate the process from creativity to customer application, ensuring that innovative results benefit more patients at the fastest speed possible

A recent survey released by the European Union Chamber of Commerce in China and consulting firm Roland Berger shows signs of a rebound in business confidence among European companies in China. China's dynamic R&D ecosystem, vast talent pool, and rapid product commercialization capabilities are attracting more and more European companies to expand their R&D activities.

Yan Ci, President of the European Union Chamber of Commerce in China, believes that the ways in which European companies participate in the Chinese market are becoming more diverse. Investment is not the only way for European companies to participate in the Chinese market, "he said. Companies can participate in China's development through investment, as well as integrate into the Chinese market through purchasing products from Chinese companies and conducting technological cooperation.

More and more foreign-funded enterprises are paying attention to China's emerging industries. In the first half of this year, the import and export of foreign-funded enterprises in the fields of electronic information and new materials increased by 57.4% and 21.4% respectively.

Yan Ci believes that many European companies hope to integrate into China's innovation ecosystem, while also facing fierce competition in the Chinese market. To stand out in the Chinese market, one must possess outstanding capabilities